Hidrocortisona Generis

Hidrocortisona Generis is a pharmaceutical product that contains the active ingredient hydrocortisone sodium succinate. It is supplied as a sterile solution for intramuscular or intravenous administration. The preparation is marketed in the European Union and is available by prescription only. As a glucocorticoid, it is used in clinical settings for its anti‑inflammatory and immunosuppressive properties, although specific strengths and dosage or other forms are not disclosed.

Hydrocortisone sodium succinate is indicated for short‑term management of severe inflammatory or immune‑mediated conditions that require rapid systemic glucocorticoid activity.

- Acute adrenal insufficiency (e.g., adrenal crisis) - Severe allergic reactions, including anaphylaxis - Acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD) - Cerebral edema associated with brain tumors or trauma - High‑dose therapy for rheumatic diseases when oral steroids are insufficient

Like other systemic glucocorticoids, hydrocortisone sodium succinate may cause a range of adverse reactions, varying in frequency and severity.

Common: - Transient elevation of blood glucose, especially in diabetic patients - Mild electrolyte changes such as sodium retention and potassium loss - Headache, dizziness, or a feeling of flushing shortly after administration - Local pain, erythema, or swelling at the injection site

Serious: - Severe hypersensitivity reactions, including anaphylaxis, urticaria, or angioedema - Acute adrenal insufficiency if high‑dose therapy is stopped abruptly - Marked hypertension, fluid retention, or pulmonary edema - Opportunistic infections, such as fungal or viral reactivation, due to immunosuppression

When prescribing hydrocortisone sodium succinate, clinicians should evaluate patient history and monitor for conditions that may be worsened by systemic glucocorticoid exposure.

- Existing uncontrolled infections, especially fungal or viral, may be exacerbated. - Patients with known hypersensitivity to hydrocortisone or excipients should avoid use. - Caution in individuals with diabetes mellitus, as glucose control may deteriorate. - Monitor blood pressure and fluid balance in patients with cardiovascular disease. - Use judiciously in pregnant or breastfeeding women; risk‑benefit assessment is required. - Assess for underlying psychiatric disorders, as glucocorticoids can affect mood and behavior.

Hydrocortisone sodium succinate can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of key interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid efficacy. - Co‑administration with other systemic corticosteroids, which can increase the risk of systemic toxicity.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration or bleeding. - Anticoagulants (e.g., warfarin) as glucocorticoids can enhance anticoagulant effects. - Vaccines, particularly live attenuated vaccines, may have reduced efficacy or cause infection. - Diuretics, especially potassium‑sparing agents, due to additive effects on electrolyte balance.